Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by an educational grant from Amgen Inc.

Oncology Briefings™: Preventing Skeletal-Related Events in Multiple Myeloma

Release Date: June 11, 2021
Expiration Date: June 11, 2022

Activity Overview

This online activity is designed to provide a concise and focused overview of current and emerging strategies for the prevention and treatment of skeletal-related events in patients with multiple myeloma (MM), the evidence regarding their efficacy and safety, how the optimal strategy is chosen in clinical practice, and the approaches for managing adverse events associated with these prevention and treatment strategies. The engaging, multimedia format of this program includes audio commentary from an expert thought leader integrated with text-based elements.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Amgen Inc. 

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical oncologists and hematologist/oncologists who treat patients with multiple myeloma. Fellows, nurses, nurse practitioners, physician assistants, and other health care professionals (HCPs) involved in the treatment of multiple myeloma are also invited to participate in this activity.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Differentiate between available bone-targeted agents for the prevention and treatment of skeletal-related events (SREs) in MM.
  • Evaluate safety and efficacy profiles from pivotal and emerging clinical trial data for bone-targeted agents in MM.
  • Determine optimal strategies to monitor and manage adverse events associated with the use of bone-targeted agents in MM.

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities.


Noopur Raje, MD
Noopur Raje, MD
Clinical Director
Center for Multiple Myeloma
Massachusetts General Hospital
Boston, MA

Disclosures: Consultant: Amgen, bluebird bio, BMS, Caribou, Celgene, Janssen.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By